Search trials – HealthDB

Активни: Recruiting ×

Намерени 4,436 изпитвания Стр. 178 от 222

Recruiting

Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom

Chronic Lymphocytic Leukemia, CLL

This is a retrospective observational research study to describe the characteristics and real-world clinical outcomes of patients with chronic lymphocytic leukaemia receiving acalabrutinib in the United Kingdom (the EPIC study). Physicians treating chronic lymphocytic leukaemia patients with acalabrutinib, where the patients started treatment as part of the acalabrutinib Early Access Programme (EAP), will be invited to recruit patients. Clinical data will be extracted from the patients' clinical records in line with local laws. Data from this study will provide UK-specific real-world data on patients who were started on acalabrutinib as part of the UK acalabrutinib EAP.

Начало: 17.10.2022 Край: 01.04.2027 Възраст: 18–130 г.

United Kingdom AstraZeneca NCT05557695

Recruiting Phase 1/2

4D-310 in Adults With Fabry Disease and Cardiac Involvement

Fabry Disease

This is a prospective multicenter, open-label, dose-escalation trial to assess the safety, tolerability, and pharmacodynamics of 4D-310 following a single IV administration. The study population is comprised of adult males and females with Fabry Disease and cardiac involvement

Начало: 16.10.2022 Край: 01.06.2030 Възраст: 18–65 г. Treatment

Australia, Taiwan 4D Molecular Therapeutics NCT05629559

Recruiting

International Multicentric Observational Study to Characterize Subpopulations of Patients With Autism Spectrum Disorder

Autism Spectrum Disorder

To determine sufficient number of biological and clinical markers to identify subgroups of potential best responders to a specific medication

Начало: 13.10.2022 Край: 31.12.2025 Възраст: 12–65 г.

Australia, Spain, United States Stalicla SA NCT05590715

Recruiting Phase 1

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

Advanced Cancer Metastatic Cancer Solid Tumor

This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway.

Начало: 10.10.2022 Край: 01.04.2028 Възраст: от 18 г.

United States Jazz Pharmaceuticals NCT05557045

Recruiting Phase 3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases +5

The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration including screening and follow-up is up to 93 weeks.

Начало: 10.10.2022 Край: 01.07.2028 Възраст: 60–85 г. Treatment

Argentina, Australia, China +5 Eli Lilly and Company NCT05508789

Recruiting

KIDSHEART AND BRAIN : Early EEG Surgery Congenital Heart Disease Predict Onset of Neurodevelopmental Disorders

Neurodevelopmental Disorders Congenital Cardiomyopathy

Congenital cardiopathy are frequent malformations (1/100 birth). The progress of surgery permit a survival rate at the adult age of more than 90%. The long terms consequences must be taken in account and the nerodevelopmental disorders are in first place (intelectual deficiency, autism spectrum disorders, or attention disorders) and presents in 30 to 60% of the patients (Calmant, 2015). The impact can be important on the scolarity, the studies, the professional activity and finaly on the quality of life of the patients becomming adults. The identification of the risk factors on surgery period should permit to propose the most adapted follow-up to the specifics needs of each patients. On the scientific plans, the identification of early markers on brain dammage on EEG should permit to better apprehend the physiopathologic mecanisms involved.

Начало: 10.10.2022 Край: 13.10.2026 Възраст: 1–1 г.

France University Hospital, Lille NCT05658965

Recruiting Phase 2

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Breast Cancer Metastatic Triple-Negative Breast Cancer

The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.

Начало: 03.10.2022 Край: 01.10.2027 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT05570253

Recruiting

Rocket Study: A Study to Characterize Biomarkers and Disease Progression in Participants With Pelizaeus-Merzbacher Disease

Pelizaeus-Merzbacher Disease

The purpose of the study is to prospectively assess longitudinal changes in proteolipid protein 1 (PLP1) protein, disease-related biomarkers in cerebral spinal fluid (CSF) and blood, neuroimaging parameters relevant to Pelizaeus-Merzbacher disease (PMD) and longitudinal changes in performance on clinical, participant, and caregiver-reported outcome assessments to inform the development of therapies for PMD.

Начало: 03.10.2022 Край: 01.03.2029 Възраст: 6–17 г.

France, Germany, Israel +4 Ionis Pharmaceuticals, Inc. NCT05659901

Recruiting Phase 3

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

A study to evaluate if the randomized addition of venetoclax to a chemotherapy backbone (fludarabine/cytarabine/gemtuzumab ozogamicin \[GO\]) improves survival of children/adolescents/young adults with acute myeloid leukemia (AML) in 1st relapse who are unable to receive additional anthracyclines, or in 2nd relapse.

Начало: 01.10.2022 Край: 01.04.2031 Възраст: 29–21 г. Treatment

Australia, Belgium, Canada +14 PedAL BCU, LLC NCT05183035

Recruiting

Efficacy of Aponeurectomy on the 2-year Recurrence Rate of Dupuytren's Disease

Dupuytren's Disease

Dupuytren's disease is a frequent hereditary disease in Northern Europe. It is a degenerative disease affecting the palmar aponeurosis of the hand. It develops a progressive contractile fibrosis which cuts the hypodermic fatty tissue, adheres to the skin and the phalanges, gradually bending the affected rays, resulting in significant functional impotence. Various medical and surgical treatments are available.

Начало: 29.09.2022 Край: 29.03.2030 Възраст: от 18 г.

France Elsan NCT05067764

Recruiting Phase 1/2

EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T

Prostate Cancer Metastatic Castration-resistant Prostate Cancer

This clinical trial will evaluate the safety and efficacy of \[161Tb\]Tb -PSMA-I\&T in men with metastatic castration-resistant prostate cancer (mCRPC).

Начало: 29.09.2022 Край: 01.12.2026 Възраст: от 18 г. Treatment

Australia Peter MacCallum Cancer Centre, Australia NCT05521412

Recruiting Phase 2

Collagen-targeted PET Imaging for Early Interstitial Lung Disease

Interstitial Lung Disease

The goal of this study is to investigate the ability of \[68Ga\]CBP8 to detect collagen deposition in early interstitial lung disease.

Начало: 28.09.2022 Край: 01.12.2026 Възраст: от 40 г.

United States Massachusetts General Hospital NCT05417776

Recruiting Phase 1

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer

Bladder Cancer

The purpose of this study is to see whether 68Gallium PSMA-PET/CT scans are an effective way to detect sites of cancer in people with metastatic bladder cancer or skin cancer. The study researchers want to learn if a 68Gallium PSMA PET/CT scan will work better, the same, or not as well as the PET/CT scans doctors usually use for imaging bladder cancer or skin cancer (FDG-PET/CT scan).

Начало: 28.09.2022 Край: 01.09.2027 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT05562791

Recruiting Phase 1

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Non-muscle-invasive Bladder Cancer NMIBC Non-Muscle Invasive Bladder Carcinoma Non-Muscle Invasive Bladder Neoplasms +2

The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.

Начало: 26.09.2022 Край: 01.03.2027 Възраст: от 18 г. Treatment

Australia, United States Aura Biosciences NCT05483868

Recruiting Phase 2/3

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

Начало: 23.09.2022 Край: 18.06.2029 Възраст: от 18 г. Treatment

Argentina, Australia, Canada +15 Janssen Research & Development, LLC NCT05327114

Recruiting Phase 3

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Relapsed or Refractory Multiple Myeloma

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Начало: 20.09.2022 Край: 30.11.2033 Възраст: от 18 г. Treatment

Argentina, Australia, Belgium +24 Celgene NCT05519085

Recruiting

A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)

Nephrotic Syndrome in Children Minimal Change Disease Focal Segmental Glomerulosclerosis

Children with steroid resistant nephrotic syndrome (SRNS) are exposed to prolonged courses of immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent need to identify novel and safe therapies to treat nephrotic syndrome in children. Stimulation of the vagus nerve, which can be activated noninvasively by transcutaneous auricular vagus nerve stimulation (taVNS), has immunomodulatory effects mediated by the inflammatory reflex and spleen. taVNS has become a therapy of interest for treating chronic immune mediated illnesses. The aims of the study are (1) To determine the feasibility of protocol implementation and tolerability of taVNS in the treatment of nephrotic syndrome in children (2) To establish proof-of-concept and generate statistical estimates of variance parameters and effect sizes for treatment response outcomes in children with nephrotic syndrome randomized to taVNS therapy compared with sham therapy (3) To investigate the effects of taVNS on inflammatory markers in children with nephrotic syndrome.

Начало: 19.09.2022 Край: 01.08.2027 Възраст: 3–17 г.

United States Northwell Health NCT05583942

Recruiting Phase 1

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 Head and Neck Carcinoma of Unknown Primary Locally Advanced Head and Neck Squamous Cell Carcinoma Locally Advanced Hypopharyngeal Squamous Cell Carcinoma +22

This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of tumor cells and may kill them. Cisplatin, which is a chemotherapy used in this trial, is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Radiation therapy uses high energy to kill tumor cells and shrink tumors. Giving ipatasertib in combination with chemo-radiation may be better than chemo-radiation alone in treating patients with advanced head and neck cancer.

Начало: 19.09.2022 Край: 01.07.2027 Възраст: от 18 г.

Canada, United States National Cancer Institute (NCI) NCT05172245

Recruiting Phase 1/2

A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

This study was an open, multicenter, dose-increasing/investigational Phase IB/II clinical trial to evaluate the efficacy of SHR-A1811 in combination with other antitumor therapies in subjects with advanced non-small cell lung cancer with HER2 . It can be divided into two parts, Part A is the dose escalation and efficacy exploration study of SHR-A1811 combined with Pyrotinib, and Part B is the dose escalation and efficacy exploration study of SHR-A1811 combined with SHR-1316.

Начало: 15.09.2022 Край: 01.12.2026 Възраст: 18–75 г.

China Jiangsu HengRui Medicine Co., Ltd. NCT05482568

Recruiting Phase 1

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Prostate Cancer Metastatic Castration-resistant Prostate Cancer Castration Resistant Prostatic Cancer

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

Начало: 15.09.2022 Край: 01.12.2028 Възраст: 18–100 г. Treatment

Australia, United States Janux Therapeutics NCT05519449

1 … 176 177 178 179 180 … 222